Analysis
Four public-markets stories converged this week, and together they show 2026's IPO market splitting into two tiers with almost nothing priced in between: Jio Platforms' mega-cap debut, Anthropic's pending blockbuster listing, and two far smaller deals from Aclaris Therapeutics and Corxel Pharmaceuticals.
How this week's deals break down by size
- Jio Platforms -- opened 21% above its IPO price for a roughly $131.9 billion debut-day valuation on a $3.2 billion raise, India's largest-ever IPO.
- Anthropic -- has filed its S-1 disclosing $16.3 billion in first-half 2026 revenue and an $80.7 billion net loss, mostly a non-cash charge; price, share count and raise size remain blank pending pricing, with reporting putting its targeted valuation near $2 trillion.
- Corxel Pharmaceuticals -- is heading public through a $377 million SPAC merger with Amanat Acquisition Corp, combining trust and PIPE proceeds.
- Aclaris Therapeutics -- priced a stock offering expected to raise about $50.0 million in gross proceeds ($46.7 million net) from 7.79 million shares plus 6.5 million pre-funded warrants at $3.50 a share, with the deal set to close Oct. 28.
“A band of deals that used to be the mid-cap tech and growth IPO market's core is simply missing this week.”
What the numbers show
Lay the four deals side by side and the gap is the headline: Jio's debut-day valuation dwarfs the other three deals combined, and even Corxel's SPAC merger -- itself a meaningful sum for most private companies -- is a rounding error next to Jio or Anthropic's pending listing. A band of deals that used to be the mid-cap tech and growth IPO market's core is simply missing this week.
Why the middle is empty
Public-market investors in 2026 appear willing to pay up for businesses that are either enormous and profitable, like Jio, or large and still-growing with a clear path to scale, like the valuation Anthropic is reportedly seeking despite its disclosed net loss. What is missing is capital for the mid-sized, moderately growing company that used to be the default tech IPO candidate a decade ago. Smaller biotech and SPAC deals like Aclaris and Corxel fill a different need -- modest capital raises for companies already public or going public through a faster SPAC route -- rather than competing for the same investor dollars as a traditional growth-stage IPO.
What to watch
Anthropic's actual pricing, whenever its S-1's blank price and share count are filled in, will be the next test of whether 2026's public markets keep rewarding scale at the very top or whether its disclosed net loss gives underwriters pause on where exactly within the range reporting has floated the deal ultimately clears.
The smaller deals are worth watching too. Aclaris and Corxel both show that even modestly sized biotech issuers can still get capital-markets deals done this year, just not at the scale or multiple that would have classified them as headline tech IPOs a decade ago. If a mid-sized tech or AI-infrastructure company tests the public markets before year-end, it will land in the gap this week's four deals left empty -- and how investors price it will say more about where 2026's IPO window actually sits than any single mega-cap debut can.